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Abstract: Chronic obstructive pulmonary disease (COPD) is predicted to become the third 
leading cause of death in the world by 2020. It is characterized by airflow limitation that 
is not fully reversible. The airflow limitation is usually progressive and associated with an 
abnormal inflammatory response of the lungs to noxious particles and gases, most commonly 
cigarette smoke. Among smokers with COPD, even following withdrawal of cigarette smoke, 
i  nflammation persists and lung function continues to deteriorate. One possible explanation 
is that bacterial colonization of smoke-damaged airways, most commonly with nontypeable 
H  aemophilus influenzae (NTHi), perpetuates airway injury and inflammation. Furthermore, 
COPD has also been identified as an independent risk factor for lung cancer irrespective of 
concomitant cigarette smoke exposure. In this article, we review the role of NTHi in airway 
inflammation that may lead to COPD progression and lung cancer promotion.
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Introduction
The pooled global prevalence of chronic obstructive pulmonary disease (COPD) 
in adults aged 40 years or older is ∼10%, and it is a leading cause of morbidity and 
m  ortality in the US.1–5 COPD is believed to be caused by inflammation induced by 
inhaled smoke and particulates, and possibly by infecting pathogens as well, leading to 
the structural changes in airways and alveoli that result in irreversible airflow limitation 
(Figure 1). Despite the fact that smoking causes most cases of COPD, only 25% of 
smokers develop COPD.6,7 Conversely, epidemiologic data indicate that approximately 
1 of 6 patients with COPD has never smoked.8 This variable susceptibility to COPD 
most likely reflects genetic variations in the inflammatory and structural responses to 
inhaled smoke and to microorganisms colonizing the airways of smokers.9–11 The most 
common colonizing bacterium is nontypeable (ie, unencapsulated) Haemophilus 
i  nfluenzae (NTHi).12,13 This organism is found in the lower respiratory tract of ∼30% of 
individuals with COPD at any time.12,14–17 In addition to colonization during c  linically 
stable periods, acquisition of new strains of NTHi is an important cause of lower 
respiratory tract infection, resulting in exacerbations of COPD.13,18–20 Together, these 
findings suggest that persistent or repetitive exposure of the airway to NTHi products 
may contribute to airway inflammation in COPD.18 Furthermore, several studies have 
found that smokers with COPD have an increased risk of lung cancer (3- to 10-fold) 
compared with smokers with comparable cigarette exposure but without COPD.21,22 
In this review, we will discuss the existing data regarding the roles that NTHi plays 
in COPD development and lung cancer promotion.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Inflammation in COPD
Based on the definition of the Global Initiative for Chronic 
Obstructive Lung Disease, COPD is “a disease state charac-
terized by airflow limitation that is not fully reversible. The 
airflow limitation is usually progressive and associated with 
an abnormal inflammatory response of the lungs to noxious 
particles and gases”.23 Although COPD and asthma both 
involve inflammation in the respiratory tract, the inflammatory 
processes differ markedly.10,24 Histopathological s  tudies show a 
predominant involvement of peripheral airways (bronchioles) 
and lung parenchyma in COPD, whereas asthma involves 
inflammation in all airways but minimal involvement of the 
lung parenchyma.25 Both innate and adaptive immune responses 
are involved in lung inflammation in patients with COPD.
Inflammatory cells
In histopathologic specimens of distal lung and in bron-
choalveolar lavage fluid (BALF) from COPD patients, 
macrophages and neutrophils are prominent.26–28 There is also 
an increase in the total numbers of T lymphocytes in lung 
parenchyma and peripheral and central airways of patients 
with COPD, with a greater increase in CD8+ than in CD4+ 
cells.25,29,30 Although the absolute number of CD8+ cells is 
more than CD4+ cells, there is strong evidence to support a 
role for CD4+ T helper 1 (Th1) cells in maintenance of chronic 
inflammation in COPD.31,32 Loss of lung function in patients 
with COPD is associated with a high percentage of CD4+ 
and CD8+ T lymphocytes that express chemokine receptors 
CCR5 and CXCR3 (markers of Th1 cells), but not CCR3 or 
CCR4 (markers of Th2 cells).33,34 CD8+ cells are typically 
increased in airway infections, and it is possible that chronic 
or recurrent colonization of the lower respiratory tract of 
COPD patients by bacterial and viral pathogens contributes 
to this inflammatory response.35 It has also been shown that 
CD8+ T cells are required for inflammation and destruction 
in cigarette smoke-induced emphysema in mice.36
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Figure 1 effects of cigarette smoke and NTHi in the pathogenesis of lung cancer and COPD. Two inputs (cigarette smoke and microbial infection, top) act on two broad 
cell types (epithelial, left, and leukocyte, right) within the lungs to induce two outputs (lung cancer and COPD, bottom) as follows. Hydrocarbons and ROS in cigarette 
smoke induce mutations in epithelial cells that initiate carcinogenesis. Hydrocarbons, ROS, and particles in smoke activate the UPR and NLRs in epithelial cells and resident 
leukocytes, such as macrophages, inducing inflammation through key mediators such as IRE1, the inflammasome, and NF-κB. Microbial infection of smoke-damaged airways, 
particularly with NTHi, results in further inflammation by activating pattern recognition receptors such as the NLRs and TLRs. Activated epithelial cells amplify inflammation 
by signaling through chemotactins, cytokines, and DAMPs to resident and recruited leukocytes (CD8+ T cells, CD4+ Th17 cells, and B cells). In turn, activated leukocytes 
signal to epithelial cells through NF-κB and STAT3 to further amplify inflammation and generate proliferative and survival signals that promote carcinogenesis. COPD results 
from phenotypic changes in epithelial cells, such as mucous metaplasia or cell death, along with other structural changes such as proliferation or death of mesenchymal cells 
and deposition or destruction of extracellular matrix that together are termed remodeling.
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  DAMPs,  damage-associated  molecular  patterns;  IRE1,  inositol-requiring  enzyme  1;  NF-κB,  nuclear 
transcription factor-κB; NLRs, Nod-like receptors; NTHi, nontypeable Haemophilus influenzae; ROS, reactive oxygen species; STAT3, signal transducer and activator of 
transcription 3; TLRs, Toll-like receptors; UPR, unfolded protein response.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The accumulated volume of B cells in small airways 
(mainly seen in lymphoid aggregates)2 and in bronchial 
bi  opsies of large airways37 is higher in patients with COPD 
than in controls without airflow limitation and even higher 
in more severe COPD. The humoral, or antibody, immune 
response is essential for host defense against viral and 
b  acterial pathogens. B cells probably contribute to the inflam-
matory process and/or the development and perpetuation of 
COPD by means of a specific antigen-driven process.38 The 
lung has the ability to respond quickly to some pathogens 
through stimulation of resident antigen-specific memory 
B cells. Alternatively, after exposure to a new pathogen, 
the lung can generate de novo both a systemic and local 
(mucosal) antibody response. The resulting production of 
antigen-specific IgG and IgA acts in concert to help clear 
the invading pathogen and reduce subsequent colonization 
of respiratory epithelium.39 Primary adaptive responses are 
triggered by immature myeloid dendritic cells (DCs), which 
carry antigen from the lungs to regional lymph nodes.40 
Antigen presentation by these mature DCs is required to 
activate naive CD4+ T cells, which are essential to generate 
polarized type 1 or type 2 responses and for robust immuno-
logic memory. Persistent and chronic inflammation recruits 
natural killer (NK) cells and more DCs.40 NK cells exposed 
to interleukin-12 (IL-12) favor survival of DCs that prime 
for Th1 responses, whereas NK cells exposed to IL-4 do not 
exert DC selection, leading to Th2 responses. Additionally, 
previous pulmonary infections or immune responses increase 
the number of lung DCs and populate the lungs with clones 
of memory B cells and T cells that are immediately available 
to respond to infections.40
In addition to the traditional Th1 and Th2 subtypes, recent 
developments in cytokine biology imply that COPD might 
be better explained by the T helper 17 (Th17) phenotype.41 
E  ffector molecules produced by CD4+ Th17 cells include 
IL-17A, IL-17F, and IL-22.41 IL-17A and IL-17F both bind to 
the IL-17 receptor (IL-17R).42 It has been shown that IL-17R 
signaling is required for lung CXC chemokine and g  ranulocyte 
colony-stimulating factor (G-CSF) ex  pression,   neutrophil 
recruitment, and host defense against Gram-  negative 
  bacteria.43 IL-17A, the prototype of this new cytokine family, 
is a 20–30-kDa glycosylated homodimeric cytokine pro-
duced predominantly by T cells.44 Many of the i  nflammatory 
effects of Th17 cells are attributed to the expression of 
IL-17A. For example, IL-17A upregulates the expression of a 
  number of CXCR2 chemokines, including CXCL1, CXCL6, 
and CXCL8, together with the neutrophil survival factors 
g  ranulocyte-macrophage colony-stimulating factor (GM-CSF) 
and G-CSF from the airway epithelium. This would suggest 
that Th17 cells are important in promoting and sustaining the 
neutrophilic inflammation observed in COPD. In addition, 
IL-17A can act synergistically with viral infection as well 
as other inflammatory mediators that include tumor n  ecrosis 
factor (TNF) to potentiate these responses.45,46 Transgenic 
overexpression of IL-17A in the lung induces inflammation 
and mucous metaplasia.47 Primary human tracheobronchial 
epithelial cells stimulated by an extensive panel of cytokines 
upregulated the MUC5AC and MUC5B genes in response to 
IL-17A.48 Additionally, IL-17A potently induces epithelial 
cells and fibroblasts to secrete neutrophil attractants, notably 
CXCL8.48–51 Finally, IL-17 family members increase the 
sensitivity of macrophages to pathogen-associated molecular 
patterns and may even directly induce TNF.51
Inflammatory mediators  
and signaling pathways
Cellular inflammation in COPD is accompanied by increased 
levels of proinflammatory cytokines, which amplify inflam-
mation via the activation of the NF-κB pathway, leading to 
increased expression of multiple inflammatory genes.52–56 
NF-κB activation occurs primarily through IκB kinase 
(IKK)-dependent phosphorylation and subsequent degrada-
tion of specific inhibitors, the IκBs, which retain NF-κB in the 
cytoplasm. Upon activation, NF-κB dimers enter the nucleus, 
where they modulate transcription of a large variety of target 
genes.52,53,57,58 These genes code for mediators of immune and 
inflammatory reactions, such as TNF, IL-1β, IL-6, IFN-γ, 
IL-18, IL-32, and Th17 cytokines, the chemokine IL-8, and 
cell adhesion molecules.
TNF is mostly produced by macrophages, and also by 
many other cells, such as mast cells, epithelial cells, and B and 
T cells, and activates NF-κB.59 TNF levels are increased in 
the sputum of patients with COPD during e  xacerbations60 
and contribute importantly to cigarette smoke-induced 
emphysema in mice.59
IL-1β stimulates alveolar macrophages from patients 
with COPD to secrete inflammatory factors,61 and together 
with TNF induces ICAM-1 expression on endothelial cells.54 
IL-18, part of the IL-1 superfamily, plays an important role 
in Th1 polarization and various Th1-type diseases, i  nducing 
TNF, IL-1β, GM-CSF, and chemokine production by mono-
cytes and T lymphocytes.62 In mouse models, it has been 
shown that constitutive IL-18 overproduction in the lungs 
induces emphysema.63
IL-6 is acutely produced by monocytes and macrophages 
at the site of inflammation, as well as by T cells in chronic International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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inflammation. IL-6 activates intracellular signaling of 
s  ignal transducer and activator of transcription 3 (STAT3) 
in epithelial and immune cells.64 STAT3 upregulation was 
observed in lung tissue from both smokers and nonsmokers 
with COPD, and this was associated with upregulation of 
its target genes.65 Increased levels of IL-6 have been found 
in induced sputum, exhaled breath condensate, and BALF 
from COPD patients,66 and when overexpressed in the mouse 
airways results in emphysema-like airspace enlargement and 
airway inflammation.67
IFN-γ is produced by Th1 cells, activated macrophages, 
and DCs, inducing them to produce IL-12, the main Th1-
inducing cytokine. When overexpressed in the murine lung 
it results in emphysema, and it has also been shown to be 
upregulated in lymphocytes isolated from emphysema-
tous lung tissue samples, BALF, and sputum from COPD 
patients.33,68,69
IL-32 produced in NK cells, T cells, epithelial cells, and 
monocytes has been recently recognized as a proinflamma-
tory cytokine.70 An increased expression of IL-32 in the lung 
tissue of patients with COPD has been demonstrated and 
correlates with the level of TNF and the degree of airway 
obstruction, suggesting that IL-32 is involved in the specific 
immune response observed in COPD and may have an impact 
on disease progression.71,72
IL-8, a CXC chemokine, is a neutrophil chemoattractant 
and activator. It is secreted by macrophages, neutrophils, 
and airway epithelial cells and may contribute to COPD 
progression by attracting neutrophils to the lung.73 Increased 
levels found in sputum samples from COPD patients cor-
relate with the airway bacterial load, and its constitutive 
overexpression in the lungs of mice induces emphysema, 
furthermore s  uggesting its important role in the pathogenesis 
of COPD.53,63
NTHi and immune responses
NTHi is a small (1.0 × 0.3 µm) Gram-negative coccobacillus 
that lacks a polysaccharide capsule (hence its nontypeable 
classification). It colonizes the upper respiratory tract of up 
to 75% of normal adults and primarily acts as a mucosal 
pathogen.74 Although it lacks a mucinous capsule, NTHi 
possesses characteristic coat proteins.
The P2 protein is the major outer membrane protein 
(OMP) of NTHi, constituting ∼50% of the protein content 
of the outer membrane. P2 is a target of human serum 
b  actericidal antibody, indicating that the protein is important 
in the human immune response to NTHi.75 P6 is a 16-kDa 
peptidoglycan-associated lipoprotein that is present in the 
outer membrane of all strains of NTHi76 and shows a high 
degree of sequence conservation among strains.77 Several 
lines of evidence suggest that P6 elicits bactericidal antibody 
responses.76,78 Berenson et al have shown that P6 is a specific 
trigger of bacteria-induced human macrophage inflammatory 
events, with IL-8 and TNF as key effectors of P6-induced 
macrophage responses.79 Another study has shown that 
although the migration of mature DCs into the pulmonary 
lymph nodes is attenuated after repeated airway challenge 
of mice with OMPs of NTHi, the in vitro P6-specific T cell 
proliferation in cultured pulmonary lymph node cells was 
enhanced and subsequently linked to the development of 
P6-specific IgA production and the development of protec-
tive immunity in the airway of mice.80
NTHi lipooligosaccharide (LOS) is a major virulence 
determinant and may play a role in colonization and inva-
sion of mucosal surfaces in the respiratory tract.81 NTHi 
LOS is analogous to the lipopolysaccharide (LPS) of enteric 
Gram-negative bacteria in that it contains lipid A linked 
by 3-deoxy-d-manno-octulosonic acid to a heterogeneous 
sugar polymer.82,83 NTHi LOS, however, differs from clas-
sic enterobacterial LPS in that it does not contain repeating 
O-antigen units and is therefore more similar to that derived 
from Neisseria and Bordetella species.82,83
Like most other bacterial infections, NTHi infections 
induce inflammation with prominent release of cytokines 
and chemokines. Extensive in vitro studies have shown that 
NTHi lysate activates the NF-κB pathway in airway epithelial 
cells and markedly increases expression and release of proin-
flammatory mediators, including IL-6, IL-8, and TNF.18,84–86 
Airway epithelial cells are capable of sensing and responding 
to inflammatory stimuli through innate immune mechanisms 
that result in lung inflammation.87 These mechanisms mostly 
function through Toll-like receptors (TLRs), a family of 
evolutionarily conserved transmembrane receptors that serve 
as pattern recognition receptors. They recognize conserved 
microbial motifs in molecules such as bacterial LPS, pepti-
doglycan, flagellin, unmethylated CpG DNA, and double- 
and single-stranded RNA. Activation of the corresponding 
TLR by any of these molecules results in the activation of 
antimicrobial responses88 and the initiation of an inflamma-
tory response, alerting the host to the presence of microbial 
invasion and initiating an immune response.89,90
Because the TLRs share sequence similarity with the IL-1 
receptor (IL-1R) family in their cytoplasmic regions, it is not 
unexpected that downstream events are mediated by com-
mon components, such as myeloid differentiation primary 
response gene (88) (MyD88). MyD88 is an adaptor protein International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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that links the IL-1R to IL-1R-associated protein kinase 
(IRAK), a serine–threonine kinase that is related to the pelle 
kinase of Drosophila. Upon binding of ligand to IL-1R, IRAK 
phosphorylates, subsequently dissociates from the receptor 
complex and associates with TNF-receptor-activated factor 
6 (TRAF6). This process results in the activation of two dif-
ferent pathways that involve the c-Jun NH2-terminal kinase 
and p38 mitogen-activated protein kinase (MAPK) family 
and the Rel family transcription factor NF-κB.91,92
TLR-4 is the signaling receptor for LPS, the major proin-
flammatory component of the Gram-negative cell wall, in 
concert with CD14, which serves as the ligand-binding part 
of the LPS receptor complex. Triggering of TLR-4 results 
in the activation of two distinct intracellular pathways, one 
that relies on the common TLR adaptor MyD88 and one 
that is mediated by Toll/IL-1R domain-containing adaptor-
inducing IFN-β (TRIF).93 Wieland et al have shown that 
alveolar macrophages from CD14 and TLR-4 knockout (KO) 
mice are virtually unresponsive to NTHi in vitro.93 I  ntranasal 
administration of NTHi in the mouse results in a brisk 
elaboration of IL-1β, IL-6, TNF, macrophage-inflammatory 
protein (MIP)-1α, and MIP-2 in BALF and a corresponding 
mobilization of intrapulmonary neutrophils. After intranasal 
infection with NTHi, CD14 and TLR-4 KO mice showed an 
attenuated early inflammatory response in their lungs with 
diminished IL-1β, IL-6, TNF, MIP-1α, and MIP-2 in BALF 
and a notable absence of intrapulmonary neutrophils, which 
was associated with a strongly reduced clearance of NTHi 
from the respiratory tract.93,94 Additionally, MyD88 KO, 
but not TRIF mutant mice, showed an increased bacterial 
load in their lungs upon infection with NTHi.93 These data 
demonstrate that the MyD88-dependent pathway of TLR-4 
is important for an effective innate immune response to respi-
ratory tract infection caused by NTHi. This suggests that the 
airway epithelia might contribute to sensing NTHi infection 
and signaling the innate immune response.94
TLR-2 also plays a critical role in mediating inflammatory 
responses against bacterial pathogens in the lung.95 NTHi 
strongly activates NF-κB in human epithelial cells via two 
distinct signaling pathways: NF-κB translocation-dependent 
and NF-κB translocation-independent pathways.85 The NF-κB 
translocation-dependent pathway involves activation of the 
NF-κB-inducing kinase (NIK)–IKKα/β complex, leading to 
IκBα phosphorylation and degradation, whereas the NF-κB 
translocation-independent pathway involves activation of 
MKK3/6-MAPK. TLR-2 is required for   NTHi-induced NF-κB 
activation through both pathways, and OMP P6 appears to also 
activate NF-κB via similar signaling   pathways.85 NTHi also 
induces COX-2 and PGE2 expression in a p38 MAPK and 
NF-κB-dependent manner through TLR2 in lung epithelial 
cells in vitro and lung tissues in vivo.96
NTHi in COPD
NTHi is frequently present in the airways of adults with 
COPD.14–17 This Gram-negative bacterium is found in the 
lower respiratory tract of ∼30% of individuals with COPD 
at any time, and with serial sampling more than 60% of 
COPD patients show colonization.97 Several studies have 
shown higher inflammatory responses in the presence of 
NTHi colonization in stable COPD patients and smokers 
without COPD.98–100 For example, colonized smokers, with 
or without COPD, had more bronchial neutrophilia compared 
with noncolonized ones.15 Bacterial colonization has also 
been associated with increased frequency of exacerbations 
and an accelerated decline in lung function.97 Furthermore, 
the acquisition of new NTHi serotypes is associated with 
exacerbations of COPD.12,13,18–20 In one study, NTHi was 
found in the bronchial tissues of 87% of patients with exac-
erbations compared with 33% of stable COPD patients and 
0% of healthy controls.14 The immune response that develops 
after an exacerbation seems to be strain specific and protects 
against recurrent exacerbation due to the homologous strain 
but leaves the patient susceptible to exacerbations caused by 
antigenically unrelated heterologous strains, and this likely 
represents a mechanism for recurrent infections.101
Studies using molecular techniques indicate that some 
patients with COPD are persistently colonized with NTHi 
even after antimicrobial therapy and despite a negative 
sputum culture. This suggests that bacteria may cause a 
greater proportion of exacerbations than is revealed by 
sputum culture alone.102–104 Defective immune responsive-
ness and impaired phagocytosis by alveolar macrophages 
might provide an immunologic basis for persistence of NTHi 
in the airways of adults with COPD.105 Cigarette smoke 
induces mucus dysfunction by several mechanisms106–110 
and ultimately increases mucin production, reduces mucus 
hydration, and decreases mucus clearance, which might 
also contribute to airway colonization in COPD patients.111 
Other possible mechanisms of colonization include airway 
epithelial cell invasion,20,103 antigenic alteration,112–114 and 
biofilm formation.115
NTHi could contribute to COPD progression by 
inducing neutrophilic influx into the airways, neutrophil 
n  ecrosis with release of neutrophil elastase and other matrix 
  metalloproteinases, and production of oxygen radicals.79,86 
These mediators can overwhelm the antiproteinase barrier of International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
118
Moghaddam et al
the lung and damage airway and alveolar structures, thereby 
amplifying smoking-induced lung damage.116 We have 
shown that weekly exposure of mice to an aerosolized NTHi 
lysate induces lung inflammation with a profile of mediators 
and inflammatory cells similar to that observed in COPD 
patients.117 Repetitive exposure to NTHi lysate results in a 
10-fold increase in total inflammatory cell numbers in BALF, 
dominated by neutrophils (81%) with fewer macrophages and 
lymphocytes. This was accompanied by marked increases 
in inflammatory cytokines (TNF and IL-6), Th1 cytokines 
(IFN-γ and IL-12), and the neutrophil   chemoattractant KC. 
Consistent with the rapid rise in the levels of inflammatory 
cytokines, NF-κB was rapidly activated after each exposure. 
In the weeks following chronic activation of this innate 
immune response, a marked COPD-like inflammatory process 
ensues. Peribronchiolar and perivascular inflammatory cell 
infiltration and lymphoid aggregates (after 8 weeks), similar 
to those described in COPD patients, were seen. The chronic 
inflammatory response was characterized by infiltration of the 
airway wall by macrophages, CD20+ B cells, CD8+ T cells, 
CD4+ T cells, and neutrophils. Structural changes in the 
lung parenchyma were closely associated with the chronic 
inflammatory response. There was increased fibrous tissue 
around airways, similar to that described in COPD patients, 
after 25 weekly NTHi exposures, and this further increased 
after 50 weeks of exposure.117 Flow cytometric analysis of 
BALF and lung homogenates after eight NTHi exposures 
has also shown an increased number of IL-17-producing 
CD4+ T cells (Th17 cells), associated with high expression of 
IL-17 in inflamed lung tissue and in the BALF (unpublished 
data). Furthermore, exposure of mice genetically deficient 
in IL-17R to the NTHi lysate resulted in a lower level of 
neutrophilic influx into the BALF and less inflammatory 
cell infiltration in lung tissue, indicating a major role for 
Th17 cells in NTHi-induced COPD-like airway inflamma-
tion (unpublished data). As transgenic overexpression of 
TNF in the airway epithelium caused BALF neutrophilia 
and inflammatory cell infiltration around airways, but not 
fibrosis,117 this suggests that innate immune inflammation 
alone is insufficient to induce airway fibrosis.
Studies have shown that both human and mouse alveolar 
epithelial type II (AT II) cells express MHC II molecules and 
that AT II cells are capable of activating T cells in vitro.118–120 
A recent study shows that naive CD4+ T cells are specifi-
cally activated against a lung-specific antigen by AT II cells 
independently of lymphoid tissue and DCs in vivo.121 These 
data offer the strongest evidence to date that the lung itself, 
independent of the classical antigen-presenting cells of the 
immune system, can present foreign and self-peptides and 
differentiate CD4+ T cells into regulatory T cell subsets.122 
We also demonstrated that NTHi lysate could induce innate 
resistance in the lungs, resulting in broad protection against 
a wide range of pathogens,87 which occurs independent 
of alveolar macrophages and recruited neutrophils. This 
protection derives from stimulation of local innate immune 
mechanisms, and activated lung epithelium is the most likely 
cellular effector of this response. Furthermore, gene expres-
sion analysis of lungs from NTHi-exposed mice demonstrated 
NF-κB signaling to be the most enriched process, followed 
closely by interferons, IL-6/STAT3, and TLR signaling, 
including MyD88, TLR-2, and TLR-4.123,124 To further dissect 
the importance of the NF-κB pathway in this phenomenon, 
we have targeted NF-κB in the airway epithelium using 
a genetic strategy and have demonstrated a lower level of 
neutrophilic influx into BALF after a single NTHi exposure 
(unpublished data). Together, these findings suggest that 
exposure of the airway to NTHi products contributes to lung 
inflammation and airway fibrosis in COPD, which is mediated 
by innate immune activation of epithelial cells that signal to 
adaptive immune cells.
NTHi, COPD, and lung cancer
Worldwide, lung cancer is the leading cause of cancer mortal-
ity and is expected to account for 30% of all male and 26% of 
all female cancer deaths in 2009.125 Cigarette smoking causes 
90% of all lung cancers and is believed to do so primarily 
by inducing DNA mutations.126 In addition, epidemiologic 
data indicate that chronic inflammation also plays a role in 
lung epithelial carcinogenesis.127 Genetic factors have also 
been shown to play a role in determining susceptibility to 
lung cancer. These genetic factors are believed to confer an 
inherent susceptibility (exaggerated or maladaptive response) 
to chronic inflammation from cigarette smoking. Consistent 
with many cancer models, this inflammatory stimulus in 
the lungs results in tissue remodeling, DNA damage, and 
impaired cell cycle control.128
Multiple studies have found that smokers with COPD 
have an increased risk of lung cancer compared with smokers 
without COPD.21,22,127,129,130 There is strong evidence that a 
patient’s forced expiratory volume in the first second of expi-
ration is an independent prognostic marker for   developing 
lung cancer in both smokers and exsmokers,129,130 and the 
incidence of lung cancer seems to be higher for those with 
more severe airflow obstruction. The presence of mild 
emphysema, even without demonstrable airflow o  bstruction, 
confers a substantial risk of developing lung cancer.131 The International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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likelihood of developing lung cancer within 10 years is 
three-fold greater in patients with mild-to-moderate COPD 
and 10-fold greater in patients with severe COPD compared 
with smokers with normal lung function.22 It has also been 
shown that increased lung cancer mortality is associated with 
a history of COPD, even among people who have never been 
active smokers.132
Several possible mechanisms may link lung cancer to 
COPD, and both genetic and environmental factors may 
play a role. This link could be related to inflammation and 
the body’s attempt to repair emphysematous airspaces.133 
On the basis of existing in vitro studies showing that 
NTHi activates proliferative and antiapoptotic signaling 
pathways,84,85,134 c  olonization with this bacterium may 
also promote   carcinogenesis by stimulating growth and 
i  nhibiting apoptosis. We have shown that NTHi-induced 
COPD-like airway inflammation promotes lung cancer in a 
Clara cell-targeted K-ras mutant mouse model (CC-LR) of 
lung cancer.135 In contrast, existing epidemiologic data do 
not suggest any definite association between allergic airway 
inflammation (including asthma) and lung cancer, and some 
even suggest a p  rotective role.136–140 To test this, CC-LR mice 
were sensitized intraperitoneally to ovalbumin (OVA) and 
then repetitively challenged with an OVA aerosol weekly 
for 8 weeks. This resulted in eosinophilic lung inflamma-
tion associated with increased levels of Th2 cytokines and 
mucous metaplasia of airway epithelium, similar to what 
is seen in asthma patients. However, this type of allergic 
inflammation did not result in a significant difference in lung 
surface tumor number.124
IL-6 has been implicated in inflammatory responses in 
human COPD,6,26 and the IL-6 pathway has been found to 
be one of the mechanisms linking inflammation to cancer.64 
Therefore, to determine the causal role of cytokines that 
mediate COPD-like inflammation in lung carcinogenesis, 
we genetically ablated IL-6 in CC-LR mice. This not only 
inhibited intrinsic lung cancer development (1.7-fold) but 
also inhibited the promoting effect of extrinsic COPD-
like airway inflammation (2.6-fold).124 Taken together, 
we found that there is a clear specificity for the nature of 
inflammation in lung cancer promotion (Th17 type), and 
IL-6 has an essential role in lung cancer promotion. We 
suggest that COPD-like airway inflammation induced by 
NTHi provides a tumor microenvironment that favors lung 
tumor promotion and progression. This occurs via release of 
inflammatory mediators (IL-6 and TNF) from innate immune 
cells (neutrophils and macrophages) secondary to activation 
of epithelial innate immune signaling pathways (MyD88/
NF-κB). This in turn activates more intracellular signaling 
pathways (NF-κB and STAT3) in the airway epithelium 
and immune cells, resulting in activation of prosurvival, 
antiapoptotic, and proangiogenic signals accompanied by 
skewing toward a protumoral adaptive immune response 
(Th17 response) (Figure 1).
Conclusion
It appears that surface components of NTHi induce lung 
inflammation by innate immune signaling mechanisms and 
that this progresses to airway fibrosis by recruitment of the 
host adaptive immune system. A straightforward strategy to 
reduce the incidence of COPD is the prevention of tobacco 
consumption. However, because of the persistent risk among 
former smokers, additional strategies that stop the progres-
sion to advanced COPD are highly attractive. Based on the 
demonstrated ability of NTHi to induce lung inflammation 
and airway fibrosis and its persistent colonization of the air-
ways of COPD patients, dissecting underlying mechanisms 
will help us to develop alternative preventive and therapeutic 
strategies in COPD patients. Furthermore, this would have 
a major impact on preventing the leading cause of cancer 
death by providing the basis for rationally directed therapy 
in patients at high risk for lung cancer development.
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